| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in investing activities | -125,751 | -134,845 |
| Proceeds from employee stock purchase plan | 1,002 | 370 |
| Proceeds from issuance of common stock upon exercise of stock options | 4,046 | 1,558 |
| Net cash provided by financing activities | 5,048 | 1,928 |
| Net decrease in cash, cash equivalents and restricted cash | -44,664 | -26,512 |
| Cash and cash equivalents at beginning of period | 128,779 | - |
| Cash and cash equivalents at end of period | 84,115 | - |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)